Advisory Commission on Childhood Vaccines, 8288-8289 [2018-03812]
Download as PDF
<![CDATA[
8288
Federal Register / Vol. 83, No. 38 / Monday, February 26, 2018 / Notices
members, including two co-chairs. The
Committee membership maintains a
balance of diverse experiences and
expertise. Those requesting
consideration require expertise in areas
such as: Public health; epidemiology;
laboratory practice; immunology;
infectious diseases; behavioral health
and science including, but not limited
to opioid use and related expertise;
health education; healthcare delivery;
state health programs; clinical care;
preventive health; medical education;
health services and clinical research;
and healthcare financing. In addition,
people living with HIV and affected
populations as well as individuals
employed by state and local health and
education agencies, HIV/viral hepatitis/
STD community-based organizations,
and the ethics or religious community
are encouraged to submit nomination
packages for consideration. Current
federal employees will not be
considered.
Written nominations for
membership to the Committee must be
received on or before May 30, 2018.
Packages received after this time will
not be considered for the current
membership cycle. (See SUPPLEMENTARY
INFORMATION, below, for required
documentation.)
DATES:
Submit your electronic
nomination package by electronic mail
to CHACAdvisoryComm@hrsa.gov.
FOR FURTHER INFORMATION CONTACT: CDR
Holly Berilla, HRSA, HIV/AIDS Bureau
by email at CHACAdvisoryComm@
hrsa.gov or by telephone at (301) 443–
9965. A copy of the Committee Charter
and background information can be
obtained by accessing the Advisory
Committee website at https://
www.cdc.gov/maso/facm/
facmchachspt.html.
ADDRESSES:
The CDC/
HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and
Treatment was established under
Section 222 of the Public Health Service
(PHS) Act, [42 U.S.C. Section 217a], as
amended.
The purpose of the Committee is to
advise the Secretary, HHS; the Director,
CDC; and the Administrator, HRSA
regarding objectives, strategies, policies,
and priorities for HIV, viral hepatitis,
and other STD prevention and treatment
efforts including surveillance of HIV
infection, AIDS, viral hepatitis, and
other STDs, and related behaviors;
epidemiologic, behavioral, health
services, and laboratory research on
HIV, viral hepatitis, and other STDs;
identification of policy issues related to
HIV/viral hepatitis/STD professional
daltland on DSKBBV9HB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:58 Feb 23, 2018
Jkt 244001
education, patient healthcare delivery,
and prevention services; Agency
policies about prevention of HIV, viral
hepatitis and other STDs, treatment,
healthcare delivery, and research and
training; strategic issues influencing the
ability of CDC and HRSA to fulfill their
missions of providing prevention and
treatment services; programmatic efforts
to prevent and treat HIV, viral hepatitis,
and other STDs; and support to the
Agencies in their developoment of
responses to emerging health needs
related to HIV, viral hepatitis, and other
STDs.
Members selected will be considered
special government employees (SGEs)
and may be invited to serve four (4) year
terms. SGEs are eligible to receive a
stipend and reimbursement for per diem
and any travel expenses incurred for
attending Committee meetings, as
authorized by section 5 U.S.C. 5703 for
persons employed intermittently in
government service. Approved
nominees will be invited to serve during
calendar year 2019.
The following information must be
included in the electronic nomination
package for each individual to be
considered for nomination: (1) A
statement clearly indicating the name
and affiliation of the nominee, the basis
for the nomination (i.e., specific
attributes such as experience, education,
current affiliations, positions, etc.), and
that the nominee is willing to serve as
a member of the Committee; (2) the
nominee’s name, address, and daytime
telephone number and the home/or
work address, and email address; and
(3) a current copy of the nominee’s
curriculum vitae. Nomination packages
may be summited directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS is required to ensure that the
membership of the Committee is
balanced in terms of points of view
represented. Every effort is made to
ensure that individuals from a broad
representation of geographic areas,
gender, ethnic and minority groups, as
well as individuals with disabilities are
given consideration for membership and
therefore, HHS encourages nominations
of qualified candidates from these
groups. HHS also encourages geographic
diversity in the composition of the
Committee. Appointments shall be
made without discrimination based on
age, ethnicity, gender, sexual
orientation, and cultural, religious, or
socioeconomic status.
Individuals who are selected for
appointment will be required to provide
detailed information regarding their
financial holdings, consultancies, and
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
research grants or contracts. Disclosure
of this information is necessary in order
to determine if the selected candidate is
involved in any activity that may pose
a potential conflict with the official
duties to be performed as a member of
the Committee.
Amy McNulty,
Acting Director, HRSA, Division of the
Executive Secretariat.
[FR Doc. 2018–03853 Filed 2–23–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Commission on Childhood
Vaccines
Health Resources and Service
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, notice
is hereby given that a meeting is
scheduled for the Advisory Commission
on Childhood Vaccines (ACCV). This
meeting will be open to the public.
Information about the ACCV and the
agenda for this meeting can be obtained
by accessing the following website:
https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html.
SUMMARY:
The meeting will be held on
March 8, 2018, at 10:00 a.m. ET.
ADDRESSES: This meeting will be held
via Adobe Connect meeting and
conference call. This is not an in-person
meeting. The public can join the
meeting by:
1. (Audio Portion) Calling the
conference phone number (800) 988–
0218 and providing the following
information:
Leader Name: Dr. Narayan Nair.
Password: 9302948.
2. (Visual Portion) Connecting to the
ACCV Adobe Connect Meeting using the
following URL: https://
hrsa.connectsolutions.com/accv/.
Participants should call and connect 15
minutes prior to the meeting in order for
logistics to be set up. If you have never
attended an Adobe Connect meeting,
please test your connection using the
following URL: https://
hrsa.connectsolutions.com/common/
help/en/support/meeting_test.htm and
get a quick overview by following URL:
https://www.adobe.com/go/connectpro_
overview.
DATES:
E:\FR\FM\26FEN1.SGM
26FEN1
Federal Register / Vol. 83, No. 38 / Monday, February 26, 2018 / Notices
FOR FURTHER INFORMATION CONTACT:
Anyone requesting information
regarding the ACCV should contact
Annie Herzog, Program Analyst,
Division of Injury Compensation
Programs (DICP), HRSA in one of three
ways: (1) Send a request to the following
address: Annie Herzog, Program
Analyst, DICP, HRSA, 5600 Fishers
Lane, 08N146B, Rockville, Maryland
20857; (2) call (301) 443–6593; or (3)
send an email to aherzog@hrsa.gov.
The ACCV will meet on Thursday,
March 8, 2018, beginning at 10:00 a.m.
via Adobe Connect Meeting; however,
meeting times and information to join
the meeting and/or conference call
could change. For the latest information
regarding meeting start time and
information to join the meeting and/or
conference call, please check the ACCV
website: https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html.
The ACCV
was established by section 2119 of the
Public Health Service Act (the Act) (42
U.S.C. 300aa–19), as enacted by Public
Law (Pub. L.) 99–660, and as
subsequently amended, and advises the
Secretary of HHS (the Secretary) on
issues related to implementation of the
National Vaccine Injury Compensation
Program (VICP).
Other activities of the ACCV include:
Recommending changes to the Vaccine
Injury Table at its own initiative or as
the result of the filing of a petition;
advising the Secretary in implementing
section 2127 of the Act regarding the
need for childhood vaccination
products that result in fewer or no
significant adverse reactions; surveying
federal, state, and local programs and
activities related to gathering
information on injuries associated with
the administration of childhood
vaccines, including the adverse reaction
reporting requirements of section
2125(b) of the Act; advising the
Secretary on the methods of obtaining,
compiling, publishing, and using
credible data related to the frequency
and severity of adverse reactions
associated with childhood vaccines;
consulting on the development or
revision of Vaccine Information
Statements; and, recommending to the
Director of the National Vaccine
Program research related to vaccine
injuries which should be conducted to
carry out the VICP.
The agenda items for the March 8,
2018, meeting will include, but are not
limited to, updates from DICP,
Department of Justice (DOJ), National
Vaccine Program Office (NVPO),
Immunization Safety Office (Centers for
daltland on DSKBBV9HB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:58 Feb 23, 2018
Jkt 244001
Disease Control and Prevention),
National Institute of Allergy and
Infectious Diseases (National Institutes
of Health) and Center for Biologics,
Evaluation and Research (Food and
Drug Administration). A draft agenda
and additional meeting materials will be
posted on the ACCV website: https://
www.hrsa.gov/advisorycommittees/
childhoodvaccines/ prior to
the meeting. Agenda items are subject to
change as priorities dictate.
Members of the public will have the
opportunity to provide comments. Oral
comments will be honored in the order
they are requested and may be limited
as time allows. Requests to make oral
comments or provide written comments
to the ACCV should be sent to Annie
Herzog by March 5, 2018, using the
address and phone number above.
Individuals who plan to participate and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify Annie Herzog, using the address
and phone number above at least 10
days prior to the meeting.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2018–03812 Filed 2–23–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Member Conflict
Applications.
Date: March 27, 2018.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
8289
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 5635 Fishers Lane Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Ranga Srinivas, Ph.D.,
Chief, Extramural Project Review Branch,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067, srinivar@
mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; NIAAA Member Conflict
Applications—AA3.
Date: April 2, 2018.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 5635 Fishers Lane, Bethesda,
MD 20892 (Telephone Conference Call).
Contact Person: Ranga Srinivas, Ph.D.,
Chief, Extramural Project Review Branch,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067, srinivar@
mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Epidemiology, Prevention
and Behavior Research Review
Subcommittee.
Date: June 4, 2018.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 5635 Fishers Lane, Terrace Level
Conference Room 508, Bethesda, MD 20892.
Contact Person: Anna Ghambaryan, M.D.,
Ph.D., Scientific Review Officer, Extramural
Project Review Branch, National Institute on
Alcohol Abuse and Alcoholism, National
Institutes of Health, 5365 Fishers Lane, Room
2019, Rockville, MD 20852, (301) 443–4032,
anna.ghambaryan@nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Clinical, Treatment and
Health Services Research Review
Subcommittee.
Date: June 15, 2018.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn San Diego Bayside,
4875 North Harbor Drive, San Diego, CA
92106.
Contact Person: Ranga Srinivas, Ph.D.,
Chief, Extramural Project Review Branch,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067, srinivar@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 83, Number 38 (Monday, February 26, 2018)]
[Notices]
[Pages 8288-8289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-03812]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration
Advisory Commission on Childhood Vaccines
AGENCY: Health Resources and Service Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, notice
is hereby given that a meeting is scheduled for the Advisory Commission
on Childhood Vaccines (ACCV). This meeting will be open to the public.
Information about the ACCV and the agenda for this meeting can be
obtained by accessing the following website: https://www.hrsa.gov/advisorycommittees/childhoodvaccines/.
DATES: The meeting will be held on March 8, 2018, at 10:00 a.m. ET.
ADDRESSES: This meeting will be held via Adobe Connect meeting and
conference call. This is not an in-person meeting. The public can join
the meeting by:
1. (Audio Portion) Calling the conference phone number (800) 988-
0218 and providing the following information:
Leader Name: Dr. Narayan Nair.
Password: 9302948.
2. (Visual Portion) Connecting to the ACCV Adobe Connect Meeting
using the following URL: https://hrsa.connectsolutions.com/accv/.
Participants should call and connect 15 minutes prior to the meeting in
order for logistics to be set up. If you have never attended an Adobe
Connect meeting, please test your connection using the following URL:
https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm and get a quick overview by following URL: https://www.adobe.com/go/connectpro_overview.
[[Page 8289]]
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the ACCV should contact Annie Herzog, Program Analyst,
Division of Injury Compensation Programs (DICP), HRSA in one of three
ways: (1) Send a request to the following address: Annie Herzog,
Program Analyst, DICP, HRSA, 5600 Fishers Lane, 08N146B, Rockville,
Maryland 20857; (2) call (301) 443-6593; or (3) send an email to
[email protected].
The ACCV will meet on Thursday, March 8, 2018, beginning at 10:00
a.m. via Adobe Connect Meeting; however, meeting times and information
to join the meeting and/or conference call could change. For the latest
information regarding meeting start time and information to join the
meeting and/or conference call, please check the ACCV website: https://www.hrsa.gov/advisorycommittees/childhoodvaccines/.
SUPPLEMENTARY INFORMATION: The ACCV was established by section 2119 of
the Public Health Service Act (the Act) (42 U.S.C. 300aa-19), as
enacted by Public Law (Pub. L.) 99-660, and as subsequently amended,
and advises the Secretary of HHS (the Secretary) on issues related to
implementation of the National Vaccine Injury Compensation Program
(VICP).
Other activities of the ACCV include: Recommending changes to the
Vaccine Injury Table at its own initiative or as the result of the
filing of a petition; advising the Secretary in implementing section
2127 of the Act regarding the need for childhood vaccination products
that result in fewer or no significant adverse reactions; surveying
federal, state, and local programs and activities related to gathering
information on injuries associated with the administration of childhood
vaccines, including the adverse reaction reporting requirements of
section 2125(b) of the Act; advising the Secretary on the methods of
obtaining, compiling, publishing, and using credible data related to
the frequency and severity of adverse reactions associated with
childhood vaccines; consulting on the development or revision of
Vaccine Information Statements; and, recommending to the Director of
the National Vaccine Program research related to vaccine injuries which
should be conducted to carry out the VICP.
The agenda items for the March 8, 2018, meeting will include, but
are not limited to, updates from DICP, Department of Justice (DOJ),
National Vaccine Program Office (NVPO), Immunization Safety Office
(Centers for Disease Control and Prevention), National Institute of
Allergy and Infectious Diseases (National Institutes of Health) and
Center for Biologics, Evaluation and Research (Food and Drug
Administration). A draft agenda and additional meeting materials will
be posted on the ACCV website: https://www.hrsa.gov/advisorycommittees/childhoodvaccines/ prior to the meeting. Agenda items are
subject to change as priorities dictate.
Members of the public will have the opportunity to provide
comments. Oral comments will be honored in the order they are requested
and may be limited as time allows. Requests to make oral comments or
provide written comments to the ACCV should be sent to Annie Herzog by
March 5, 2018, using the address and phone number above. Individuals
who plan to participate and need special assistance, such as sign
language interpretation or other reasonable accommodations, should
notify Annie Herzog, using the address and phone number above at least
10 days prior to the meeting.
Amy McNulty,
Acting Director, Division of the Executive Secretariat.
[FR Doc. 2018-03812 Filed 2-23-18; 8:45 am]
BILLING CODE 4165-15-P
